Earnings ·
Reports Q3 net loss of $37.8M; doses first patient in TEMPO-1 study
CRBPCorbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings reported a net loss of approximately $37.8 million for the third quarter ended September 30, 2026, compared to a $23.3 million loss in the prior-year period. Operating expenses rose by $14.4 million to $38.8 million, driven primarily by a $15.0 million development milestone payment under its licensing agreement for sutantatug envedotin. The company holds $115.3 million in cash and investments, which management expects will fund operations into 2028. Clinically, Corbus initiated dosing in the registrational TEMPO-1 Phase 3 study of sutantatug envedotin for oropharyngeal cancer and reported positive topline data from the CANYON-1 Phase 1b obesity study of CRB-913, showing a mean weight loss of 5% at 60 mg after 12 weeks. Corbus Pharmaceuticals is a clinical-stage company developing therapies in oncology and obesity.